WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New search    Hide text from Guidelines

L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

This group comprises preparations used in the treatment of malignant neoplastic diseases, and immunomodulating agents.

Corticosteroids for systemic use, see H02.


L03 IMMUNOSTIMULANTS

Immunosuppressants, see L04A.


L03A IMMUNOSTIMULANTS

Levamisole, which also affects the immune response, is classified in P02CE.


L03AB Interferons

Peginterferon alfa-2b in combination with ribavirin and peginterferon alfa-2a in combination with ribavirin are classified in L03AB60 and L03AB61, respectively.

The DDD for interferon alfa is based on the treatment of chronic active hepatitis B, whilst the DDD for interferon beta is based on the treatment of multiple sclerosis.

The DDDs of interferon beta-1a is based on i.m. administration.


List of abbreviations

Last updated: 2018-12-13